Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Simple impedimetric sensor for rapid lipase activity quantification.

Zlatev R, Stoytcheva M, Valdez B, Montero G, Toscano L.

Talanta. 2019 Oct 1;203:161-167. doi: 10.1016/j.talanta.2019.05.059. Epub 2019 May 16.

PMID:
31202322
2.

UV Sensitivity of MOS Structures with Silicon Nanoclusters.

Curiel M, Nedev N, Paz J, Perez O, Valdez B, Mateos D, Arias A, Nesheva D, Manolov E, Nedev R, Dzhurkov V.

Sensors (Basel). 2019 May 17;19(10). pii: E2277. doi: 10.3390/s19102277.

3.

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.

Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH.

Lancet Haematol. 2019 May;6(5):e266-e275. doi: 10.1016/S2352-3026(19)30023-7. Epub 2019 Mar 22.

PMID:
30910541
4.

Subjective cognitive concern in multiple sclerosis is associated with reduced thalamic and cortical gray matter volumes.

Kletenik I, Alvarez E, Honce JM, Valdez B, Vollmer TL, Medina LD.

Mult Scler J Exp Transl Clin. 2019 Feb 13;5(1):2055217319827618. doi: 10.1177/2055217319827618. eCollection 2019 Jan-Mar.

5.

Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.

Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL.

Neurology. 2019 Feb 12;92(7):e723-e732. doi: 10.1212/WNL.0000000000006916. Epub 2019 Jan 11.

PMID:
30635477
6.

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.

Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS.

Lancet Haematol. 2018 Nov;5(11):e532-e542. doi: 10.1016/S2352-3026(18)30156-X.

PMID:
30389035
7.

Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.

Valdez BC, Tang X, Li Y, Murray D, Liu Y, Popat U, Champlin RE, Andersson BS.

Exp Hematol. 2018 Nov;67:49-59.e1. doi: 10.1016/j.exphem.2018.08.002. Epub 2018 Aug 10.

PMID:
30102945
8.

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.

Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1602-1609. doi: 10.1016/j.bbmt.2018.02.020. Epub 2018 Mar 2.

PMID:
29501779
9.

Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells.

Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS.

Oncotarget. 2017 Dec 17;9(3):3908-3921. doi: 10.18632/oncotarget.23386. eCollection 2018 Jan 9.

10.

Rapid reagent-less on-line H2O2 quantification in alkaline semiconductor etching solution, Part 2: Nephelometry application.

Zlatev R, Stoytcheva M, Valdez B.

Talanta. 2018 Mar 1;179:594-600. doi: 10.1016/j.talanta.2017.11.059. Epub 2017 Nov 28.

PMID:
29310281
11.

Ultra-short echo time images quantify high liver iron.

Doyle EK, Toy K, Valdez B, Chia JM, Coates T, Wood JC.

Magn Reson Med. 2018 Mar;79(3):1579-1585. doi: 10.1002/mrm.26791. Epub 2017 Jun 22.

12.

Rapid reagent-less on-line H2O2 quantification in alkaline semiconductor etching solution.

Zlatev R, Stoytcheva M, Valdez B, Ramos R.

Talanta. 2017 Aug 15;171:39-44. doi: 10.1016/j.talanta.2017.04.055. Epub 2017 Apr 26.

PMID:
28551151
13.

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.

Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M.

Lancet Haematol. 2017 Jun;4(6):e283-e292. doi: 10.1016/S2352-3026(17)30080-7. Epub 2017 May 15.

14.

Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions.

Valdez BC, Hassan M, Andersson BS.

Exp Hematol. 2017 Aug;52:65-71. doi: 10.1016/j.exphem.2017.04.011. Epub 2017 May 4.

15.

The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.

Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS.

Leuk Lymphoma. 2017 Nov;58(11):2705-2716. doi: 10.1080/10428194.2017.1306647. Epub 2017 Apr 10.

16.

Does Contracting with Managed Care Organizations Remain A Barrier for Nurse Practitioners?

Bellot J, Valdez B, Altdoerffer K, Quiaoit Y, Bronzell-Wynder T, Cunningham P.

Nurs Econ. 2017 Mar-Apr;35(2):57-63.

PMID:
29985569
17.

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.

Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE.

Bone Marrow Transplant. 2017 Apr;52(4):580-587. doi: 10.1038/bmt.2016.322. Epub 2016 Dec 19.

18.

Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.

Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2017 Feb;23(2):285-292. doi: 10.1016/j.bbmt.2016.11.001. Epub 2016 Nov 2.

19.

Evaluation of the Safety, Cell Migration, and Mucoadhesive Properties of a Mucoadhesive Polymer Blend in Human Oral Mucosa.

Song G, Banov D, Bassani AS, Valdez BC.

AAPS PharmSciTech. 2017 Jul;18(5):1617-1623. doi: 10.1208/s12249-016-0630-z. Epub 2016 Sep 19.

PMID:
27645471
20.

Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.

Valdez BC, Li Y, Murray D, Brammer JE, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS.

Oncotarget. 2016 Sep 27;7(39):63829-63838. doi: 10.18632/oncotarget.11561.

21.

Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.

Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1792-1800. doi: 10.1016/j.bbmt.2016.06.023. Epub 2016 Jul 1.

22.

Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.

Valdez BC, Brammer JE, Li Y, Murray D, Teo EC, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS.

Leuk Res. 2016 Aug;47:100-8. doi: 10.1016/j.leukres.2016.05.019. Epub 2016 May 27.

23.

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS.

Cancer. 2016 Sep 1;122(17):2680-8. doi: 10.1002/cncr.30100. Epub 2016 May 20.

24.

Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect?

Andersson BS, Valdez BC.

Bone Marrow Transplant. 2016 Jul;51(7):919-20. doi: 10.1038/bmt.2016.110. Epub 2016 Apr 25. No abstract available.

PMID:
27111045
25.

Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.

Teo EC, Valdez BC, Ji J, Li Y, Liu Y, Brammer JE, Hosing C, Nieto Y, Champlin RE, Andersson BS.

Leuk Lymphoma. 2016 Nov;57(11):2644-52. doi: 10.3109/10428194.2016.1157871. Epub 2016 Mar 16.

PMID:
26980288
26.

Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.

Ji J, Valdez BC, Li Y, Liu Y, Teo EC, Nieto Y, Champlin RE, Andersson BS.

Exp Hematol. 2016 Jun;44(6):458-65. doi: 10.1016/j.exphem.2016.03.001. Epub 2016 Mar 11.

27.

Romidepsin targets multiple survival signaling pathways in malignant T cells.

Valdez BC, Brammer JE, Li Y, Murray D, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS.

Blood Cancer J. 2015 Oct 16;5:e357. doi: 10.1038/bcj.2015.83.

28.

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.

Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1914-20. doi: 10.1016/j.bbmt.2015.06.003. Epub 2015 Jun 11.

29.

Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.

Valdez BC, Li Y, Murray D, Ji J, Liu Y, Popat U, Champlin RE, Andersson BS.

Exp Hematol. 2015 Jun;43(6):448-61.e2. doi: 10.1016/j.exphem.2015.02.001. Epub 2015 Feb 19.

30.

Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.

Song G, Valdez BC, Li Y, Liu Y, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1687-95. doi: 10.1016/j.bbmt.2014.08.003. Epub 2014 Aug 9.

31.

Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines.

Valdez BC, Zander AR, Song G, Murray D, Nieto Y, Li Y, Champlin RE, Andersson BS.

Blood Cancer J. 2014 Jan 10;4:e171. doi: 10.1038/bcj.2013.69.

32.

The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.

Song G, Valdez BC, Li Y, Dominguez JR, Corn P, Champlin RE, Andersson BS.

Leuk Lymphoma. 2014 Jul;55(7):1625-34. doi: 10.3109/10428194.2013.856007. Epub 2014 Feb 4.

33.

LabVIEW 2010 Computer Vision Platform Based Virtual Instrument and Its Application for Pitting Corrosion Study.

Ramos R, Zlatev R, Valdez B, Stoytcheva M, Carrillo M, García JF.

J Anal Methods Chem. 2013;2013:193230. doi: 10.1155/2013/193230. Epub 2013 Apr 4.

34.

Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.

Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS.

Exp Hematol. 2013 Aug;41(8):719-30. doi: 10.1016/j.exphem.2013.04.009. Epub 2013 May 3.

35.

Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB.

Biol Blood Marrow Transplant. 2013 Mar;19(3):410-7. doi: 10.1016/j.bbmt.2012.10.029. Epub 2012 Nov 2.

36.

High sensitive trypsin activity evaluation applying a nanostructured QCM-sensor.

Stoytcheva M, Zlatev R, Cosnier S, Arredondo M, Valdez B.

Biosens Bioelectron. 2013 Mar 15;41:862-6. doi: 10.1016/j.bios.2012.08.039. Epub 2012 Aug 30.

PMID:
22964383
37.

Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.

Valdez BC, Nieto Y, Murray D, Li Y, Wang G, Champlin RE, Andersson BS.

Exp Hematol. 2012 Oct;40(10):800-10. doi: 10.1016/j.exphem.2012.06.001. Epub 2012 Jun 9.

38.

High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.

Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB.

Biol Blood Marrow Transplant. 2012 Nov;18(11):1677-86. doi: 10.1016/j.bbmt.2012.05.011. Epub 2012 May 27.

39.

Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines.

Valdez BC, Murray D, Nieto Y, Li Y, Wang G, Champlin RE, Andersson BS.

Leuk Lymphoma. 2012 May;53(5):973-81. doi: 10.3109/10428194.2011.634043. Epub 2011 Dec 6.

40.

Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.

Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE.

Biol Blood Marrow Transplant. 2011 Jun;17(6):893-900. doi: 10.1016/j.bbmt.2010.09.022. Epub 2010 Oct 11.

41.

The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.

Valdez BC, Li Y, Murray D, Champlin RE, Andersson BS.

Biochem Pharmacol. 2011 Jan 15;81(2):222-32. doi: 10.1016/j.bcp.2010.09.027. Epub 2010 Oct 8.

42.

Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.

Valdez BC, Andersson BS.

Environ Mol Mutagen. 2010 Jul;51(6):659-68. doi: 10.1002/em.20603. Review.

43.

In vitro Actinomyces israelii biofilm development on IUD copper surfaces.

Carrillo M, Valdez B, Vargas L, Alvarez L, Schorr M, Zlatev R, Stoytcheva M.

Contraception. 2010 Mar;81(3):261-4. doi: 10.1016/j.contraception.2009.09.008. Epub 2009 Oct 29.

PMID:
20159185
44.

5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.

Valdez BC, Li Y, Murray D, Corn P, Champlin RE, Andersson BS.

Leuk Res. 2010 Mar;34(3):364-72. doi: 10.1016/j.leukres.2009.08.014. Epub 2009 Sep 3.

45.

Leptospirillum ferrooxidans based Fe2+ sensor.

Stoytcheva M, Zlatev R, Magnin JP, Ovalle M, Valdez B.

Biosens Bioelectron. 2009 Oct 15;25(2):482-7. doi: 10.1016/j.bios.2009.08.019. Epub 2009 Aug 22.

PMID:
19729293
46.

Developing alliances: how advanced practice nurses became part of the prescription for Pennsylvania.

Hansen-Turton T, Ritter A, Valdez B.

Policy Polit Nurs Pract. 2009 Feb;10(1):7-15. doi: 10.1177/1527154408330206.

PMID:
19383617
47.

Altered gene expression in busulfan-resistant human myeloid leukemia.

Valdez BC, Murray D, Ramdas L, de Lima M, Jones R, Kornblau S, Betancourt D, Li Y, Champlin RE, Andersson BS.

Leuk Res. 2008 Nov;32(11):1684-97. doi: 10.1016/j.leukres.2008.01.016. Epub 2008 Mar 12.

48.

c-Jun supports ribosomal RNA processing and nucleolar localization of RNA helicase DDX21.

Holmström TH, Mialon A, Kallio M, Nymalm Y, Mannermaa L, Holm T, Johansson H, Black E, Gillespie D, Salminen TA, Langel U, Valdez BC, Westermarck J.

J Biol Chem. 2008 Mar 14;283(11):7046-53. doi: 10.1074/jbc.M709613200. Epub 2008 Jan 7.

49.

Insurers' contracting policies on nurse practitioners as primary care providers: the current landscape and what needs to change.

Hansen-Turton T, Ritter A, Begun H, Berkowitz SL, Rothman N, Valdez B.

Policy Polit Nurs Pract. 2006 Aug;7(3):216-26.

PMID:
17071708
50.

Insurer policies create barriers to health care access and consumer choice.

Hansen-Turton T, Ritter A, Rothman N, Valdez B.

Nurs Econ. 2006 Jul-Aug;24(4):204-11, 175.

PMID:
16967891

Supplemental Content

Loading ...
Support Center